L. Zhang

755 citations
24 papers · 547 indexed · 1 hit paper · h-index 8
Topics
Lung Cancer Treatments and Mutations (20 papers)Lung Cancer Research Studies (9 papers)Cancer therapeutics and mechanisms (7 papers)

In The Last Decade

L. Zhang

23 papers receiving 542 citations

Hit Papers

Afatinib versus gefitinib in patients with EGFR mutation-...20172026202020232017100200300

Peers

L. Zhang
Comparison fields: 5 of 50
  • Pulmonary and Respiratory Medicine 473
  • Oncology 409
  • Molecular Biology 153
  • Cancer Research 89
  • Organic Chemistry 27
Replace Alicyn Campbell with:
Alicyn Campbell United States
Hillary E. Mulvey United States
Takao Shirai Japan
Emily Feld United States
Changli Wang China
Enrica Capelletto Italy
F Bianchi Italy
F. Eskens Netherlands
Fernando Barata Portugal
Haruto Hirano Japan
L. Zhang relative to Alicyn Campbell United States Alicyn Campbell's profile →
Citations per field
00.5×4.1×
Alicyn Campbell · 1×
Citations per year

Countries citing papers authored by L. Zhang

Since Specialization
Citations

This map shows the geographic impact of L. Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Zhang more than expected).

Fields of papers citing papers by L. Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Zhang. The network helps show where L. Zhang may publish in the future.

Co-authorship network of co-authors of L. Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of L. Zhang. A scholar is included among the top collaborators of L. Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Zhang. L. Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 9
3 1
4 1
5 1
6 7
7 5
8
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialbreakdown →
398
9 1
10
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) (Conference Abstract)
1
11 0
12 9
13 1
14 3
15 1
16 1
17 12
18 13
19 18
20 22

About L. Zhang

L. Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 24 papers that have together received 547 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (7 papers). The work is most often cited by research in Oncology (409 citations), Pulmonary and Respiratory Medicine (473 citations) and Cancer Research (89 citations). L. Zhang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Tony Mok, Luis Paz‐Ares, Vera Hirsh, Kenneth J. O’Byrne, James Chih‐Hsin Yang, Michael Boyer, Jean Fan, K. Park, Angela Märten and Yajun Shi. Their work appears in journals such as Annals of Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026